UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934 (Amendment No.           )

Filed by the Registrant 

Filed by a Party other than the Registrant 

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12

ACORDA THERAPEUTICS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

(1)

Title of each class of securities to which transaction applies:

 

 

(2)

Aggregate number of securities to which transaction applies:

 

 

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

 

(4)

Proposed maximum aggregate value of transaction:

 

 

(5)

Total fee paid:

 

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

(1)

Amount Previously Paid:

 

 

(2)

Form, Schedule or Registration Statement No.:

 

 

(3)

Filing Party:

 

 

(4)

Date Filed:

 


 


 

 

May 22, 2020

 

 

Dear Stockholder:

 

We have previously sent you proxy materials for the Annual Meeting of Stockholders of Acorda Therapeutics, Inc. taking place on June 15, 2020. Your Board of Directors recommends that stockholders vote FOR all of the proposals on the agenda.

 

Since approval of certain of the proposals requires the affirmative vote of a majority of the outstanding shares, your vote is important, no matter how many or how few shares you may own. You should have already received voting instructions/materials, but for your convenience we have included a copy of either a voting instruction form or a proxy card with this letter.

 

If you have not already done so, please vote TODAY--via the Internet or by telephone using the enclosed instructions, or alternatively by signing, dating and returning the enclosed voting instruction form or proxy card in the postage-paid envelope provided.

 

 

Very truly yours,

 

 

Andrew Mayer

Deputy General Counsel and Corporate Secretary

 

 

 

 

REMEMBER:

You can vote your shares via the Internet or by telephone or alternatively by signing, dating and returning the enclosed voting instruction form or proxy card.

 

Please follow the instructions on the enclosed voting instruction form

or proxy card to cast your vote.

 

If you have any questions, or need assistance in voting

your shares, please call our proxy solicitor:

 

INNISFREE M&A INCORPORATED

TOLL-FREE, at 1-877-717-3929

 

 

 

 

Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Acorda Therapeutics Charts.
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Acorda Therapeutics Charts.